IBP (Indication Based Pricing)
Listado de revistas y artículos seleccionados
- American Journal of Public Health
- Annals of Internal Medicine
- Annals of Oncology
- Applied Health Economics and Health Policy
- How to Cost the Implementation of Major System Change for Economic Evaluations: Case Study Using Reconfigurations of Specialist Cancer Surgery in Part of London, England
- Pricing and Reimbursement of Patent‑Protected Medicines: Challenges and Lessons from South‑Eastern Europe
- Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
- Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India's National Publicly Financed Health Insurance Scheme
- Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies
- Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost‑Effectiveness Results
- Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations
- Atención Primaria
- British Medical Journal (BMJ)
- Canadian Medical Association Journal
- Cancer Discovery
- Circulation
- Clinical Pharmacology & Therapeutics
- The “Coming of Age” of Real-World Evidence in Drug Development and Regulation
- Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value
- When Can We Trust Real-World Data To Evaluate New Medical Treatments?
- When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?
- Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan
- Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design
- When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?
- Regulator-Requested Non-Interventional Postauthorization Safety and Effectiveness Studies for Oncology Drugs: A Systematic Review
- Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data
- Cochrane Library
- Diabetes Cares
- EMBO Journal
- Epidemiology
- European Journal of Health Economics
- European Journal of Hospital Pharmacy. Science and Practice
- Improving the aseptic transfer procedures in hospital pharmacies part C: evaluation and redesign of the transfer process
- Budget impact analysis of two pharmaceutical management models in relation to the administration of intravenous anti-infective therapy in a Spanish nursing home - ProQuest
- 1ISG-023 Pharmacoeconomic analysis of reference bevacizumab: opportunity for improved efficiency - ProQuest
- European Journal of Public Health
- Gaceta Sanitaria
- Health Affairs
- How Price Regulation Is Needed To Advance Market Competition - ProQuest
- New Medicare Technology Add-On Payment Could Be Used As A Market Support Mechanism To Accelerate Antibiotic Innovation - ProQuest
- Price Differences To Insurers For Infused Cancer Drugs In Hospital Outpatient Departments And Physician Offices - ProQuest
- Health Economics
- Health Economics Review
- The cost-utility of early use of high-flow nasal cannula in bronchiolitis
- Using point-of-care diagnostic testing for improved antibiotic prescription: an economic model
- Arrangements with the NHS for providing healthcare services: do they improve financial performance of private for-profit hospitals in Spain?
- Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis
- Micro-costing in health and medicine: a critical appraisal
- Health Economics, Policy and Law
- Health Services Research
- International Journal of Technology Assessment in Health Care
- International Journal on Quality in Health Care
- Journal of American Medical Association (JAMA) / JAMA Oncology
- Joint Commission Journal on Quality Improvement
- Journal of Clinical Epidemiology
- Journal of Clinical Oncology
- Journal of Comparative Effectiveness Research
- Journal of Epidemiology & Community Health
- Journal of General Internal Medicine
- Journal of Health Economics
- Hospital Pricing Following Integration with Physician Practices
- Alternative payment models and physician treatment decisions: Evidence from lower back pain
- The economics of medical procedure innovation
- Does the framing of patient cost-sharing incentives matter? the effects of deductibles vs. no-claim refunds
- Journal of Healthcare Quality Research
- Journal of Public Health Medicine
- The Lancet (UK)
- Lancet Oncology
- Medical Care
- Medical Care Research and Review
- Does the Implementation of Reference Pricing Result in Reduced Utilization? Evidence From Inpatient and Outpatient Procedures
- The Price to Consumers of Generic Pharmaceuticals: Beyond the Headlines
- Incorporating Prescription Drug Utilization Information Into the Marketplace Risk Adjustment Model Improves Payment Accuracy and Reduces Adverse Selection Incentives
- Medical Decision Making
- Medicina Clínica (Barcelona)
- Natura
- New England Journal of Medicine
- Pharmacoeconomics
- The Challenges of Outcomes‑Based Contract Implementation for Medicines in Europe - ProQuest
- Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates - ProQuest
- A Practical Guide to Modeling and Conducting a Cost‑Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper - ProQuest
- Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia - ProQuest
- Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine - ProQuest
- Plos Medicine
- Precision and Future Medicine
- Revista Española de Salud Pública
- Revista Española Economía de la Salud
- Social Science & Medicine
- Product patents and access to innovative medicines
- Hospital response to a case-based payment scheme under regional global budget: The case of Guangzhou in China
- Microcredit as a public health initiative? Exploring mechanisms and pathways to health and wellbeing
- Willingness to pay for quality and length of life gains in end of life patients of different ages
- Healthcare policy by other means: Cancer clinical research as “oncopolicy”
- The Office of Health Economics
- Payment Models for Multi-Indication Therapies
- A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
- The Lower Drug Costs Now Act and Pharmaceutical Innovation
- Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
- Exploring the Financial Sustainability of Gene Therapies
- The Promise of Gene Therapies: Are we Ready?
- Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
- Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
- It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?
- Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
- Therapeutics and Clinical Risk Management
- Value in Health
- Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands
- A Perspective on Suitability of a Cost-Based Pricing Methodology for Repurposed Orphan Medicines: A Consideration of the Overall Value Proposition
- Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020
- Branded Price Variation in the United States Drug Market, 2010 to 2019
- Drug Prices and Value of Oncology Drugs in Italy
- Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Report
Extras:
- National Institute for Health and Care Excellence (NICE, UK)
- Institute for Clinical and Economics Review (ICER, USA)